

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2291)

DISCLOSEABLE TRANSACTIONS THE SUBSCRIPTIONS OF STRUCTURED DEPOSIT PRODUCTS

THE SUBSCRIPTIONS OF STRUCTURED DEPOSIT PRODUCTS

On January 11, 2024, ScienTech Beijing, a wholly-owned subsidiary of the Company, entered into the Structured Deposit Product Agreement I with Bank of Ningbo (Beijing branch), pursuant to which, ScienTech Beijing agreed to subscribe the Structured Deposit Product I of RMB30 million from Bank of Ningbo (Beijing branch).

On January 11, 2024, Shanghai Shape, a wholly-owned subsidiary of the Company, entered into the Structured Deposit Product Agreement II with Bank of Ningbo (Shanghai branch), pursuant to which, Shanghai Shape agreed to subscribe the Structured Deposit Product II of RMB70 million from Bank of Ningbo (Shanghai branch).

LISTING RULES IMPLICATIONS

The respective subscription of the Structured Deposit Product I and the Structured Deposit Product II, on a standalone basis, does not constitute a discloseable transaction for the Company under Chapter 14 of the Listing Rules.

As the Structured Deposit Product I and the Structured Deposit Product II subscribed by ScienTech Beijing and Shanghai Shape were offered by the same bank within a 12 month-period and were of similar nature, such Subscriptions would be aggregated for the purpose of computing the relevant percentage ratios pursuant to Rule 14.22 of the Listing Rules. As the highest applicable percentage ratio, on an aggregated basis, as calculated under Rule 14.07 of the Listing Rules is more than 5% but less than 25%, such Subscriptions constitute discloseable transactions of the Company which would be subject to the announcement requirement but exempt from the Shareholders' approval requirement under Chapter 14 of the Listing Rules.

THE SUBSCRIPTIONS OF STRUCTURED DEPOSIT PRODUCTS

Structured Deposit Product Agreement I

On January 11, 2024, ScienTech Beijing, a wholly-owned subsidiary of the Company, entered into the Structured Deposit Product Agreement I with Bank of Ningbo (Beijing branch), pursuant to which, ScienTech Beijing agreed to subscribe the Structured Deposit Product I of RMB30 million from Bank of Ningbo (Beijing branch).

The key terms of the Structured Deposit Product Agreement I are set out in the table below.

(1) Date of the subscription:	January 11, 2024
(2) Name of product:	Unit Structured Deposit (單位結構性存款)
(3) Parties:	(i) Bank of Ningbo (Beijing branch)
	(ii) ScienTech Beijing
(4) Type of product:	principal-guaranteed with floating interest rate
(5) Risk level of product (internal risk rating by the bank):	R1 (cautious)
(6) Principal amount of the subscription:	RMB30 million
(7) Term of investment:	166 days
(8) Value date:	January 12, 2024
(9) Expiry date:	June 26, 2024
(10) Expected annualized rate of return:	ranging from 1.00% to 2.90% per annum
(11) Investment scope of the product:	the interest on such deposit is linked to the fluctuations in interest rates, exchange rates, indices. Deposit interest is determined based on the EUR to USD spot price published by the foreign exchange market and determined by Bloomberg
(12) Termination and redemption:	ScienTech Beijing has no right of early termination or redemption

Structured Deposit Product Agreement II

On January 11, 2024, Shanghai Shape, a wholly-owned subsidiary of the Company, entered into the Structured Deposit Product Agreement II with Bank of Ningbo (Shanghai branch), pursuant to which, Shanghai Shape agreed to subscribe the Structured Deposit Product II of RMB70 million from Bank of Ningbo (Shanghai branch).

The key terms of the Structured Deposit Product Agreement II are set out in the table below.

(1) Date of the subscription:	January 11, 2024
(2) Name of product:	Unit Structured Deposit (單位結構性存款)
(3) Parties:	(i) Bank of Ningbo (Shanghai branch)
	(ii) Shanghai Shape
(4) Type of product:	principal-guaranteed with floating interest rate
(5) Risk level of product (internal risk rating by the bank):	R1 (cautious)
(6) Principal amount of the subscription:	RMB70 million
(7) Term of investment:	273 days
(8) Value date:	January 12, 2024
(9) Expiry date:	October 16, 2024
(10) Expected annualized rate of return:	ranging from 1.50% to 2.90% per annum
(11) Investment scope of the product:	the interest on such deposit is linked to the fluctuations in interest rates, exchange rates, indices. Deposit interest is determined based on the EUR to USD spot price published by the foreign exchange market and determined by Bloomberg
(12) Termination and redemption:	Shanghai Shape has no right of early termination or redemption

BASIS OF DETERMINING THE CONSIDERATION

The Directors confirmed that the consideration and the terms of the Subscriptions were determined after arm's length negotiation between the Company and Bank of Ningbo (including its Beijing and Shanghai branches).

REASONS AND BENEFIT OF THE SUBSCRIPTIONS

The Structured Deposit Product I and the Structured Deposit Product II subscribed by the Group offered by Bank of Ningbo (including its Beijing and Shanghai branches) are of a principal-guaranteed nature, and the Subscriptions were used by the Company for treasury management purpose in order to maximize its return on the surplus capital. Given that (i) the Structured Deposit Product I and the Structured Deposit Product II are highly secured and with low risk involved, (ii) compared with the deposit interest rates generally offered by commercial banks in the PRC, the return of the Structured Deposit Product I and the Structured Deposit Product II are relatively high; and (iii) the Structured Deposit Product I and the Structured Deposit Product II were funded by the Group's internal financial resources (idle funds) with a relatively short term which will not affect the operational liquidity of the Group, the Group decided to subscribe for the Structured Deposit Product I and the Structured Deposit Product II to improve the utilization of its

idle funds and generate better returns for the Group. The Company has implemented adequate and appropriate internal control procedures to ensure the Subscriptions would not affect the working capital or the operations of the Company, and that such investments would be conducted on the principle of protecting the interests of the Company and the Shareholders as a whole.

In light of the above, the Directors (including independent non-executive Directors) are of the view that the Subscriptions are on normal commercial terms, and the terms contained therein are fair and reasonable and in the best interests of the Company and its Shareholders as a whole.

In addition, the Company did not utilize any of the net proceeds raised from the Global Offering for the Subscriptions.

PARTIES INFORMATION

Information on the Company

The Company is a joint stock limited liability company established in the PRC on January 29, 2021. The Company is a leading interventional medical device provider in China for congenital heart diseases, a major field of application for structural heart diseases. The Company is principally engaged in the research, development, manufacture and commercialization of interventional medical devices primarily targeting structural heart diseases.

Information on ScienTech Beijing

ScienTech Beijing is a limited liability company established in the PRC on February 27, 2023, which is a wholly-owned subsidiary of the Company. ScienTech Beijing is principally engaged in research and development, production, sales, and leasing of medical devices.

Information on Shanghai Shape

Shanghai Shape is a limited liability company established in the PRC on May 5, 1994, which is a wholly-owned subsidiary of the Company. Shanghai Shape is principally engaged in the business of research, development and sales of interventional treatment series occluders for defective congenital heart disease.

Information on Bank of Ningbo

Bank of Ningbo is a joint-stock commercial bank with independent legal personality, whose A shares are listed on the Shenzhen Stock Exchange (stock code: 002142). Bank of Ningbo principally engages in the provision of banking and the relevant financial services.

As of the date of this announcement and to the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, each of Bank of Ningbo and its ultimate beneficial owner is a third party independent of the Company and its connected persons (as defined under the Listing Rules).

LISTING RULES IMPLICATIONS

The respective subscription of the Structured Deposit Product I and the Structured Deposit Product II, on a standalone basis, does not constitute a discloseable transaction for the Company under Chapter 14 of the Listing Rules.

As the structured deposits subscribed by ScienTech Beijing and Shanghai Shape under the Structured Deposit Product Agreement I and the Structured Deposit Product Agreement II were offered by the same bank within a 12 month-period and were of similar nature, such Subscriptions would be aggregated for the purpose of computing the relevant percentage ratios pursuant to Rule 14.22 of the Listing Rules. As the highest applicable percentage ratio, on an aggregated basis, as calculated under Rule 14.07 of the Listing Rules is more than 5% but less than 25%, such Subscriptions constitute discloseable transactions of the Company which would be subject to the announcement requirement but exempt from the Shareholders' approval requirement under Chapter 14 of the Listing Rules.

DEFINITIONS

“Bank of Ningbo”	Bank of Ningbo Corporation, a joint-stock commercial bank with independent legal personality, the A shares of which are listed on the Shenzhen Stock Exchange (stock code: 002142)
“Board”	the board of directors of the Company
“Company”	LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (樂普心泰醫療科技(上海)股份有限公司), a joint stock limited liability company established in the PRC on January 29, 2021
“Directors”	director(s) of the Company
“EUR”	Euro, the lawful currency of the member states of the European Union
“Global Offering”	has the meaning ascribed to it under the Prospectus
“Hong Kong”	the Hong Kong Special Administrative Region of the People's Republic of China
“Listing Rules”	Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“PRC”	the People's Republic of China excluding, for the purpose of this announcement, Hong Kong, Macau and Taiwan
“Prospectus”	the prospectus issued by the Company on October 27, 2022 in connection with the Hong Kong public offering of the Shares
“ScienTech Beijing”	LEPU ScienTech (Beijing) Medical Technology Co., Ltd.* (樂普心泰(北京)醫療科技股份有限公司), a limited liability company established in the PRC on February 27, 2023
“Shanghai Shape”	Shanghai Shape Memory Alloy Co., Ltd.* (上海形狀記憶合金材料有限公司), a limited liability company established under the laws of the PRC on May 5, 1994 and a wholly-owned subsidiary of the Company
“Share(s)”	ordinary share(s) in the share capital of our Company with a par value of RMB1.00 each

“Shareholder(s)”	holder(s) of Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Subscriptions”	Subscriptions of the Structured Deposit Product I and the Structured Deposit Product II
“RMB”	Renminbi, the lawful currency of PRC
“Structured Deposit Product Agreement I”	the agreement entered into between ScienTech Beijing and Bank of Ningbo (Beijing branch) on January 11, 2024 in relation to the subscription of Structured Deposit Product I of RMB30 million
“Structured Deposit Product Agreement II”	the agreement entered into between Shanghai Shape and Bank of Ningbo (Shanghai branch) on January 11, 2024 in relation to the subscription of Structured Deposit Product II of RMB70 million
“Structured Deposit Product I”	the structured deposit product of RMB30 million subscribed by ScienTech Beijing from Bank of Ningbo (Beijing branch) on January 11, 2024 pursuant to the Structured Deposit Product Agreement I
“Structured Deposit Product II”	the structured deposit products of RMB100 million subscribed by Shanghai Shape from Bank of Ningbo (Shanghai branch) on January 11, 2024 pursuant to the Structured Deposit Product Agreement II
“USD”	U.S. dollar, the lawful currency of the United States of America
“%”	per cent

By order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

Shanghai, the People’s Republic of China
January 11, 2024

As at the date of this announcement, the Board comprises Ms. Chen Juan and Ms. Zhang Yuxin as executive Directors, Mr. Fu Shan and Mr. Zheng Guorui as non-executive Directors, and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Liu Daozhi as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name “LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.”.*

For identification purposes only.